A Look At Cellebrite DI (CLBT) Valuation After FedRAMP High Authorization Win

Simply Wall St.

May 12

Cellebrite DI (NasdaqGS:CLBT) just cleared a key regulatory hurdle, with its Cellebrite Government Cloud platform receiving FedRAMP High Authorization backed by the U.S. Department of Justice, opening...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2634154256"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634154256\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634154256?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","is_english":true,"pubTime":"2026-05-12 06:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634154256","market":"nz","top_or_hot":-1,"title":"A Look At Cellebrite DI (CLBT) Valuation After FedRAMP High Authorization Win","media":"Simply Wall St.","content":"<div>\n<p>Cellebrite DI (NasdaqGS:CLBT) just cleared a key regulatory hurdle, with its Cellebrite Government Cloud platform receiving FedRAMP High Authorization backed by the U.S. Department of Justice, opening...</p>\n\n<a href=\"https://simplywall.st/stocks/us/software/nasdaq-clbt/cellebrite-di/news/a-look-at-cellebrite-di-clbt-valuation-after-fedramp-high-au\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Cellebrite DI (CLBT) Valuation After FedRAMP High Authorization Win</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Cellebrite DI (CLBT) Valuation After FedRAMP High Authorization Win\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-12 06:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/software/nasdaq-clbt/cellebrite-di/news/a-look-at-cellebrite-di-clbt-valuation-after-fedramp-high-au><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cellebrite DI (NasdaqGS:CLBT) just cleared a key regulatory hurdle, with its Cellebrite Government Cloud platform receiving FedRAMP High Authorization backed by the U.S. Department of Justice, opening...</p>\n\n<a href=\"https://simplywall.st/stocks/us/software/nasdaq-clbt/cellebrite-di/news/a-look-at-cellebrite-di-clbt-valuation-after-fedramp-high-au\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4613","symbol_name":"AI应用软件","start_time":0,"source_url":"https://simplywall.st/stocks/us/software/nasdaq-clbt/cellebrite-di/news/a-look-at-cellebrite-di-clbt-valuation-after-fedramp-high-au","article_id":"2634154256","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nasdaq-clbt/cellebrite-di/news/a-look-at-cellebrite-di-clbt-valuation-after-fedramp-high-au","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2634154256","pubTimestamp":1778538328,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Cellebrite DI (NasdaqGS:CLBT) just cleared a key regulatory hurdle, with its Cellebrite Government Cloud platform receiving FedRAMP High Authorization backed by the U.S. Department of Justice, opening easier access to federal cloud-based investigative workloads.\nSee our latest analysis for Cellebrite DI.\nDespite the FedRAMP milestone and recent executive changes, the stock is trading at US$13.05 after a 1 month share price gain of 18.31%, while the year to date share price return is down...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4613":"AI应用软件","BK4023":"应用软件","CLBT":"Cellebrite"},"translate_title":"赢得FedRAMP高授权后Cellebrite DI(CLBT)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLBT":1.5},"content_text":"Cellebrite DI (NasdaqGS:CLBT) just cleared a key regulatory hurdle, with its Cellebrite Government Cloud platform receiving FedRAMP High Authorization backed by the U.S. Department of Justice, opening easier access to federal cloud-based investigative workloads. See our latest analysis for Cellebrite DI. Despite the FedRAMP milestone and recent executive changes, the stock is trading at US$13.05 after a 1 month share price gain of 18.31%, while the year to date share price return is down 26.85% and the 3 year total shareholder return is up around 7x. If this kind of government grade cloud story has your attention, it could be a good moment to see what else is out there through 38 AI infrastructure stocks. With FedRAMP High status in hand, recent executive hires, and the stock still well below analyst targets despite a very large three year return, is Cellebrite now underappreciated value, or is the market already factoring in future growth? AdvertisementMost Popular Narrative: 40% Undervalued The most followed narrative pegs Cellebrite DI's fair value at $21.67 compared with the last close at $13.05, framing a sizable valuation gap for investors to unpack.  The continued transition to a recurring, subscription-based revenue model, with over 90% of revenues now from subscriptions and growing SaaS and cloud penetration, improves revenue visibility, predictability, and operating leverage, which is already translating into higher EBITDA and free cash flow margins and is likely underappreciated in current valuations.  Read the complete narrative. Want to see what is baked into that confidence? The narrative leans heavily on recurring revenue, margin expansion, and a richer earnings multiple than many software peers. Result: Fair Value of $21.67 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the story can change quickly if US federal contract delays persist, or if tighter privacy rules start to limit how much agencies can actually use these tools. Find out about the key risks to this Cellebrite DI narrative. Next Steps Feeling encouraged by the tone of this story, or wondering if it is too optimistic? Take a closer look now and weigh those potential bright spots against your own risk tolerance, starting with 4 key rewards. Looking for more investment ideas? If Cellebrite has sparked your interest, do not stop here. Fresh opportunities across sectors could fit your style even better, so give yourself room to compare.  Target higher potential total returns by scanning a curated set of screener containing 21 high quality undiscovered gems that combine strong fundamentals with underfollowed stories. Strengthen portfolio resilience by focusing on companies in the 70 resilient stocks with low risk scores that score well on financial and risk checks. Boost the quality of your income stream by reviewing the 12 dividend fortresses offering yields that stand out without ignoring balance sheet strength.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}